Soligenix Launches Phase 2 Trial for SGX945 in Behçet`s Disease
14 Nov 2024 //
PR NEWSWIRE
FDA Grants Soligenix "Fast Track" Designation for Dusquetide
08 Jan 2024 //
PRESS RELEASE
Key Binding Characteristics of Dusquetide to Intracellular Protein Identified
01 Jun 2022 //
PRNEWSWIRE
Dusquetide Shows +ve Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
04 Jan 2022 //
PRNEWSWIRE
Soligenix completes enrollment in phase 3 DOM-INNATE trial of SGX942
26 Jun 2020 //
PHARMABIZ
Soligenix Completes Enrollment in its Pivotal Ph 3 Trial of SGX942
24 Jun 2020 //
PRNEWSWIRE